| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10006324 | HBV | ENSG00000160752.15 | protein_coding | FDPS | No | No | 2224 | A0A087X090 P14324 |
| TVIS10003145 | HBV | ENSG00000160752.15 | protein_coding | FDPS | No | No | 2224 | A0A087X090 P14324 |
| TVIS10022102 | HBV | ENSG00000160752.15 | protein_coding | FDPS | No | No | 2224 | A0A087X090 P14324 |
| TVIS10025984 | HBV | ENSG00000160752.15 | protein_coding | FDPS | No | No | 2224 | A0A087X090 P14324 |
| TVIS10051965 | HBV | ENSG00000160752.15 | protein_coding | FDPS | No | No | 2224 | A0A087X090 P14324 |
| TVIS10052093 | HBV | ENSG00000160752.15 | protein_coding | FDPS | No | No | 2224 | A0A087X090 P14324 |
| TVIS30025272 | HIV | ENSG00000160752.15 | protein_coding | FDPS | No | No | 2224 | A0A087X090 P14324 |
| TVIS30025273 | HIV | ENSG00000160752.15 | protein_coding | FDPS | No | No | 2224 | A0A087X090 P14324 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | FDPS |
|---|---|
| DrugBank ID | DB00884 |
| Drug Name | Risedronic acid |
| Target ID | BE0000776 |
| UniProt ID | P14324 |
| Regulation Type | inhibitor |
| PubMed IDs | 10620343; 11752352; 16006204; 11160603; 16835450; 18056045 |
| Citations | Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ: Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone. 2005 Sep;37(3):349-58.@@Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.@@Ortiz-Gomez A, Jimenez C, Estevez AM, Carrero-Lerida J, Ruiz-Perez LM, Gonzalez-Pacanowska D: Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate. Eukaryot Cell. 2006 Jul;5(7):1057-64.@@Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH: Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007 Nov;1117:209-57. |
| Groups | Approved; Investigational |
| Direct Classification | Bisphosphonates |
| SMILES | OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O |
| Pathways | Risedronate Action Pathway |
| PharmGKB | PA451255 |
| ChEMBL | CHEMBL923 |
